Bioventus (NASDAQ:BVS) Upgraded at Barrington Research

Bioventus (NASDAQ:BVS) was upgraded by analysts at Barrington Research to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

Separately, Weiss Ratings reiterated a “hold (c-)” rating on shares of Bioventus in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Bioventus presently has a consensus rating of “Buy”.

Bioventus Stock Up 0.1%

NASDAQ:BVS opened at $8.52 on Monday. The stock has a 50-day simple moving average of $7.72 and a 200 day simple moving average of $7.28. Bioventus has a 52-week low of $5.81 and a 52-week high of $11.25. The company has a market cap of $705.12 million, a PE ratio of 71.01 and a beta of 0.80. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.14 and a current ratio of 1.74.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.